Hostname: page-component-cd9895bd7-fscjk Total loading time: 0 Render date: 2024-12-23T14:00:32.627Z Has data issue: false hasContentIssue false

Malignant hyperthermia susceptibility revealed by increased serum creatine kinase concentrations during statin treatment

Published online by Cambridge University Press:  23 December 2004

R. Krivosic-Horber
Affiliation:
Department of Anaesthesia and Intensive Care 1, University Hospital, Lille, France
T. Dépret
Affiliation:
Department of Anaesthesia and Intensive Care 1, University Hospital, Lille, France
J. M. Wagner
Affiliation:
Department of Anaesthesia and Intensive Care, University Hospital, Strasbourg, France
C. A. Maurage
Affiliation:
Department of Neuropathology, University Hospital, Lille, France
Get access

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Correspondence
Copyright
2004 European Society of Anaesthesiology

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Farmer JA. Learning from the cerivastatin experience. Lancet 2001; 358: 383385.Google Scholar
Ucar M, Mjorndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Safety 2000; 22: 441457.Google Scholar
Urwyler A, Deufel T, McCarthy T, West S. European Malignant Hyperthermia Group. Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia. Br J Anaesth 2001; 86: 283287.Google Scholar
Weglinski MR, Wedel DJ, Engel AG. Malignant hyperthermia testing in patients with persistently increased serum creatine kinase levels. Anesth Analg 1997; 84: 10381041.Google Scholar
Pasternak RC, Smith SC, Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002; 40: 567572.Google Scholar
Ording H. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH group. Results of testing patients surviving fulminant MH and unrelated low-risk subjects. Acta Anaesthesiol Scand 1997; 41: 955966.Google Scholar